Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGA039 in Healthy Volunteers and Von Willebrand Disease (VIVID)
NCT05776069Phase 2Recruiting
- Sponsor
- Vega Therapeutics
- Start
- Mar 2023
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of vga039 in von Willebrand disease (VWD), sponsored by Vega Therapeutics. Started Mar 2023; status: recruiting.
02
Drugs
vga039
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT05776069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776069.